Notice of Voluntary Dismissal to be filed in Bayer case, first scheduled Zantac trial GSK did not settle Plaintiff ongoing litigation inconsistent with scientific consensus, GSK will continue to defend all claims vigorously
We have introduced more conservatism in our estimates and as a result our valuation resets to £371.0m or 172p/share (previously £631.3m or 293p/share).